WNT5A and breast carcinoma: To distinguish between these possibilities, we treated Vangl overexpressing breast cancer cells with the Porcupine antagonist C59, which impairs palmitoylation and subsequent secretion of Wnt ligands [55], to deplete endogenous Wnt5a ligand.